Spots Global Cancer Trial Database for immune therapy
Every month we try and update this database with for immune therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China | NCT04740996 | Head and Neck S... | Pembrolizumab | 18 Years - | ChineseAMS | |
| Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | NCT03493932 | Glioblastoma | Nivolumab BMS-986016 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study | NCT04047602 | Brain Tumor Brain Metastase... Brain Cancer | Reduced Dose SR... | 18 Years - | Indiana University | |
| Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | NCT03592706 | HepatoCellular ... Liver Cancer | IKC (Immune Kil... TACE (Transcath... | 20 Years - 79 Years | Ivy Life Sciences, Co., Ltd | |
| A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma | NCT04501094 | Urothelial Canc... | Bintrafusp alfa... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China | NCT04857164 | Head and Neck S... | Pembrolizumab c... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus | NCT03792347 | Esophageal Squa... | Pembrolizumab | 18 Years - 75 Years | Ruijin Hospital | |
| Intratumoral TriMix Injections in Early Breast Cancer Patients | NCT03788083 | Breast Cancer F... Early-stage Bre... | Trimix Placebo | 18 Years - 85 Years | Universitair Ziekenhuis Brussel | |
| Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment | NCT05443230 | Liver Cancer Sarcopenia | gait speed; ct ... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| PROvenge Treatment and Early Cancer Treatment | NCT00779402 | Prostate Cancer | Control Sipuleucel-T | 18 Years - 80 Years | Dendreon | |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05267626 | Advanced Solid ... Metastatic Canc... | AU-007 Aldesleukin | 18 Years - | Aulos Bioscience, Inc. | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | NCT05335928 | Myocarditis Acu... Cancer | Abatacept plus Placebo | 18 Years - | Massachusetts General Hospital | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | NCT02097732 | Metastatic Mela... Brain Metastase... | Ipilimumab Stereotactic Ra... | 18 Years - | University of Michigan Rogel Cancer Center | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | NCT04611126 | Metastatic Ovar... Metastatic Fall... Peritoneal Canc... | Ipilimumab Cyclophosphamid Fludarabine Pho... Tumor Infiltrat... Nivolumab Relatlimab | 18 Years - 75 Years | Herlev Hospital | |
| A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | NCT00381173 | Breast Cancer Ovarian Cancer Prostate Cancer Colon Cancer Renal Cancer | Cyclophosphamid... | 18 Years - | Eisai Inc. | |
| Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | NCT00074490 | Lymphoma Leukemia Myeloproliferat... Multiple Myleom... Myelodysplastic... | Rituximab Fludarabine Etoposide Doxorubicin Vincristine Cyclophosphamid... Peripheral bloo... T cell donor ly... Prednisone Allogeneic hema... Filgrastim T-Rapa cell Don... | 11 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | NCT04615143 | Recurrent Hepat... | Tislelizumab Tislelizumab co... | 18 Years - 75 Years | Sun Yat-sen University | |
| Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases | NCT05129202 | Non Small Cell ... | immune therapy | 18 Years - | Hunan Province Tumor Hospital | |
| A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 | NCT00852007 | Prostate Cancer | DC-Tn-MUC1: aut... | 19 Years - | McMaster University | |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | NCT00951457 | Leukemia, Lymph... | Bendamustine Alemtuzumab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer | NCT02580045 | Metastatic Canc... Advanced Cancer Brain Metastasi... | 18 Years - | Duke University | ||
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Sipuleucel-T Manufacturing Demonstration Study | NCT01477749 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | sipuleucel-T | 18 Years - | Dendreon | |
| SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients | NCT03716596 | Pancreatic Canc... | SBRT anti-PD-1 antib... | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | NCT00738829 | Leukemia, Lymph... | Lenalidomide Fludarabine Rituximab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding Immunotherapy: A Qualitative and Quantitative Mixed Methods Study | NCT05740800 | Supportive Care... Immunotherapy | 20 Years - 100 Years | National Taiwan University Hospital | ||
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | NCT05335928 | Myocarditis Acu... Cancer | Abatacept plus Placebo | 18 Years - | Massachusetts General Hospital | |
| Intratumoral TriMix Injections in Early Breast Cancer Patients | NCT03788083 | Breast Cancer F... Early-stage Bre... | Trimix Placebo | 18 Years - 85 Years | Universitair Ziekenhuis Brussel | |
| ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study | NCT06095674 | Cervical Cancer | Anti-PD-1 antib... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | NCT04303117 | Kaposi Sarcoma | NHS-IL12 M7824 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer | NCT00045968 | Glioblastoma Mu... Glioblastoma GBM Grade IV Astroc... Glioma Brain Cancer Brain Tumor | Dendritic cell ... | 18 Years - 70 Years | Northwest Biotherapeutics | |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | NCT01431391 | Prostatic Neopl... Prostate Cancer Prostatic Adeno... | sipuleucel-T leuprolide acet... | 18 Years - | Dendreon | |
| NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | NCT04303117 | Kaposi Sarcoma | NHS-IL12 M7824 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | NCT03911557 | Tumor, Solid | Durvalumab and ... | 18 Years - | University of Kentucky | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer | NCT03030131 | Carcinoma, Non-... | Durvalumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | NCT00738829 | Leukemia, Lymph... | Lenalidomide Fludarabine Rituximab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China | NCT04857164 | Head and Neck S... | Pembrolizumab c... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | NCT00065442 | Prostate Cancer | Sipuleucel-T APC-Placebo | 18 Years - | Dendreon | |
| To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | NCT00715078 | Prostate Cancer | sipuleucel-T | 18 Years - | Dendreon | |
| Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | NCT03406468 | Non-Small Cell ... | Radiotherapy | 18 Years - | Maastricht Radiation Oncology | |
| Sipuleucel-T Manufacturing Demonstration Study | NCT01477749 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | sipuleucel-T | 18 Years - | Dendreon | |
| GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | NCT02759588 | Ovarian Cancer Peritoneal Carc... Fallopian Tube ... | GL-ONC1 alone, ... | 21 Years - | Genelux Corporation | |
| Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | NCT00951457 | Leukemia, Lymph... | Bendamustine Alemtuzumab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | NCT03406468 | Non-Small Cell ... | Radiotherapy | 18 Years - | Maastricht Radiation Oncology | |
| ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | NCT04904185 | Malignant Melan... | Cyclophosphamid... Fludarabine Pho... Multiple Antige... Pembrolizumab | 18 Years - 75 Years | Herlev Hospital | |
| SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients | NCT03716596 | Pancreatic Canc... | SBRT anti-PD-1 antib... | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | NCT03406468 | Non-Small Cell ... | Radiotherapy | 18 Years - | Maastricht Radiation Oncology | |
| Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | NCT00901342 | Prostate Cancer | sipuleucel-T | 18 Years - | Dendreon | |
| Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | NCT03592706 | HepatoCellular ... Liver Cancer | IKC (Immune Kil... TACE (Transcath... | 20 Years - 79 Years | Ivy Life Sciences, Co., Ltd | |
| A Phase I Extension Trial of Repeated Infusions of ISF35 | NCT00783588 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| CAcTUS - Circulating Tumour DNA Guided Switch | NCT03808441 | Melanoma | ctDNA analysis | 16 Years - | The Christie NHS Foundation Trust | |
| Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China | NCT04740996 | Head and Neck S... | Pembrolizumab | 18 Years - | ChineseAMS | |
| Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 | NCT04999800 | Head and Neck S... | Pembrolizumab Anlotinib | 18 Years - | ChineseAMS | |
| Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | NCT04235777 | Urothelial Canc... Bladder Cancer Genitourinary C... Urogenital Neop... Urogenital Canc... | M7824 M9241 Stereotactic bo... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
